dalfampridine-ER 10mg

DRUG3 trials

Sponsors

Acorda Therapeutics

Conditions

Cerebral Palsy (CP)Multiple SclerosisPost-Ischemic Stroke

Phase 1

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

CompletedNCT01468350

Acorda TherapeuticsCerebral Palsy (CP)

Start: 2011-12-31End: 2013-03-31Updated: 2014-06-24

Phase 3

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

CompletedNCT01328379

Acorda TherapeuticsMultiple Sclerosis

Start: 2011-03-31End: 2012-07-31Updated: 2013-09-05

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

CompletedNCT02271217

Acorda TherapeuticsPost-Ischemic Stroke

Start: 2014-12-31End: 2016-10-31Updated: 2018-06-07

Related Papers

A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke

Restorative Neurology and Neuroscience2020-07-083 citations

Safety, Tolerability, and Sensorimotor Effects of Extended-release Dalfampridine in Adults With Cerebral Palsy: A Pilot Study

Clinical Therapeutics2017-01-25

Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.

2015-11-1017 citations